Fig. 1: Magnitude and breadth of SARS-CoV-2-specific immune response.
a Total anti-SARS-CoV-2 spike IgG antibody titres by indirect ELISA29 in 22 seronegative controls, 24 asymptomatic and 82 mildly symptomatic healthcare workers (HCWs) with PCR-confirmed SARS-CoV-2 infection, 7 hospitalised patients with severe or critical PCR-confirmed SARS-CoV-2 infection, 9 PCR-negative inpatient controls, and 11 pre-pandemic controls. b Ex vivo IFN-γ ELISpot showing the effector T cell responses to summed SARS-CoV-2 peptide pools spanning spike, accessory and structural proteins (E, M, NP, ORF 3, ORF6, ORF7 and ORF8), in silico-predicted pools10 and the CEF T cell control panel in cohort groups as in a. c Ex vivo IFN-γ ELISpot showing the magnitude and breadth of effector T cell responses in 54 individual volunteers to 12 SARS-CoV-2 spike peptide pools (numbered P1 to P12) and d M, NP and accessory proteins ORF 3, ORF6, ORF7 and ORF8 in 73 HCWs convalescent with mildly symptomatic SARS-CoV-2 infection. X axis shows number of days from onset of symptoms (not to scale), with blank columns representing zero response in the individual tested at that time-point. SFC/106 PBMC = spot-forming cells per million peripheral blood mononuclear cells, with background subtracted. Plots show median with error bars indicating ± IQR. Kruskal–Wallis one-way ANOVA, with Dunn’s multiple comparisons test, was performed. Two-tailed P-values < 0.05 are shown on plots with Supplementary Table 3 showing full Kruskal–Wallis one-way ANOVA, with Dunn’s multiple comparisons test for b. Source data are available in the source data file.
